In vivo dosimetry in external beam photon radiotherapy: Requirements and future directions for research, development, and clinical practice
- PMID: 33458335
- PMCID: PMC7807612
- DOI: 10.1016/j.phro.2020.08.003
In vivo dosimetry in external beam photon radiotherapy: Requirements and future directions for research, development, and clinical practice
Abstract
External beam radiotherapy with photon beams is a highly accurate treatment modality, but requires extensive quality assurance programs to confirm that radiation therapy will be or was administered appropriately. In vivo dosimetry (IVD) is an essential element of modern radiation therapy because it provides the ability to catch treatment delivery errors, assist in treatment adaptation, and record the actual dose delivered to the patient. However, for various reasons, its clinical implementation has been slow and limited. The purpose of this report is to stimulate the wider use of IVD for external beam radiotherapy, and in particular of systems using electronic portal imaging devices (EPIDs). After documenting the current IVD methods, this report provides detailed software, hardware and system requirements for in vivo EPID dosimetry systems in order to help in bridging the current vendor-user gap. The report also outlines directions for further development and research. In vivo EPID dosimetry vendors, in collaboration with users across multiple institutions, are requested to improve the understanding and reduce the uncertainties of the system and to help in the determination of optimal action limits for error detection. Finally, the report recommends that automation of all aspects of IVD is needed to help facilitate clinical adoption, including automation of image acquisition, analysis, result interpretation, and reporting/documentation. With the guidance of this report, it is hoped that widespread clinical use of IVD will be significantly accelerated.
Keywords: Electronic portal imaging device; External beam radiotherapy; In vivo dosimetry; Review; Task group report.
© 2020 The Authors.
Conflict of interest statement
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: I Olaciregui-Ruiz and B Mijnheer declare that their department licensed portal dosimetry software to Elekta Oncology Systems Ltd. for the development of the iViewDose product. This product is currently not commercially available. P Greer declares research collaborations with Varian Medical Systems. B McCurdy declares funded research collaborations on EPID dosimetry with Varian Medical Systems. N. Jornet declares that she is member of the European scientific advisory board of Sun Nuclear. F Verhaegen declares research collaborations and a patent on in vivo dosimetry with Varian Medical Systems.
Figures
References
-
- Miften M, Olch A, Mihailidis D, Moran J, Pawlicki T, Molineu A, et al. Tolerance limits and methodologies for IMRT measurement-based verification QA: Recommendations of AAPM Task Group No. 218. Med Phys 2018;45:e53-83. doi: 10.1002/mp.12810. - PubMed
-
- International Atomic Energy Agency. Development of Procedures for In Vivo Dosimetry in Radiotherapy. IAEA Human Health Report No. 8. Vienna: International Atomic Energy Agency; 2013. doi: 10.1016/0167-8140(90)90102-3.
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous
